Responses

This article has a correction. Please see:

Download PDFPDF

Modified release prednisone in patients with rheumatoid arthritis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Re:Has modified release prednisone any clinical advantage over immediate release prednisone in patients with rheumatoid arthritis?

    We thank dr Bannwarth for his comments, indicating that dividing prednison treatment over the day might be as effective as using a modified release preparation. This has not been evaluated in a clinical study, so there is no evidence to support or refute this suggestion. However, the discussed modified release preparation is especially developed to target the nadir in the cortisol rhythm, which is quite different from div...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Has modified release prednisone any clinical advantage over immediate release prednisone in patients with rheumatoid arthritis?

    Dear Editor,

    I read with interest the editorial on modified release (MR) prednisone in patients with rheumatoid arthritis (RA)[1]. In brief, it can be inferred from available data that the only clinical advantage of MR prednisone over immediate release (IR) prednisone was a decrease in duration of morning stiffness [1]. Of note, patients received IR prednisone in the morning. Due to its short duration of action, low-dos...

    Show More
    Conflict of Interest:
    None declared.